that are involved in antiviral effector function 10 .
Type I IFN signaling plays important role in the pathogenesis of Human Immunodeficiency Virus type 1 (HIV-1) infection 2, 3, 11 . Reverse transcribed proviral DNA is recognized by cGAS to trigger production of type I IFNs 12 . Virus-dependent upregulation of ISGs including IS15, MX1, OAS3, and IRF7 occurs in infected CD4 + T cells 11 . Several cellular antiviral effector ISGs can interfere with various stages of HIV-1 replication, including CNP, TRIM5α, APOBEC3G, tetherin (CD317), SAMHD1, MX2 and IFI16 [13] [14] [15] [16] [17] [18] [19] .
HIV-1 evolved strategies to evade many of these factors through its proteins such as Vif, Vpu and capsid 13, 20, 21 .
Here, we identify a new ISG C19ORF66 (synonym: FLJ11286) which codes for an uncharacterized protein UPF0515 of previously unknown function. We describe the novel effector function of C19ORF66
as an inhibitor of HIV-1 replication. Statistical analysis. Error bars in the graph depict the standard deviation. P-values were calculated by the two-tailed student's t-test and significance was indicated if p value is p<0.05 (*); p<0.001 (**); p<0.0001 (***).
RESULTS
C19ORF66 is an ISG that inhibits HIV-1 production. Unbiased RNA sequencing analysis of IFN-α stimulated cells revealed the induction of C19ORF66. This gene and its promoter showed cis-element binding sites for transcription factors IRF1, IRF7A and STAT1, confirming it as a downstream target of IFN signaling. Moreover this locus in chromosome 19 is flanked by genes involved in inflammatory and IFN signaling pathways such as TYK2, ANGPTL6, ICAM1, ICAM3 and ICAM4, further suggesting an important role in innate and inflammatory responses.
Whole PBMC and blood monocytes showed significant upregulation of C19ORF66 mRNA following 6 hours of IFN-α treatment (Fig. 1a ), and HeLa cells showed corresponding expression of endogenous 35 kDa C19ORF66 protein at 6 hours as well as a minor isoform species of 30 kDa after 24-48 hours (Fig.   1b ). When HIV-1-based lentiviral vectors were constructed to deliver genes for C19ORF66 and other candidate ISGs, viral particle production of the C19ORF66 vector 10-fold reduced compared to the vector control and most other ISG vectors (Fig. 1c ). C19ORF66 expression did not exert any cytotoxicity. Flow P a g e 9 o f 2 4
cytometry analysis of transduced 293-FT cells confirmed the lack of production of lentiviral particles with the C19ORF66 gene ( Fig. 1d and Extended Data Fig. 1 ). This occurrence was also seen for 293T cells transfected with whole wild-type proviral HIV-1 when co-transfected with an expression vector for the C19ORF66 gene, which reduced both intracellular p24 expression and release of p24 virions (Fig. 1e) .
These findings suggested that C19ORF66, Suppressor of Viral Activity-1, SVA-1, is an antiviral effector in the IFN-α mediated innate immune response.
SVA isoforms vary in their antiviral activities and localization patterns. To further characterize
SVA-1, we examined its isoforms utilizing pseudotyped lentiviral vector system. Due to alternative splicing event, various protein isoforms were reported in reference database (Extended Data Fig. 2 ). We (Fig. 2a ). The first 163 amino acids of the full SVA-1 are shared with the X4 and XN isoforms, but both these variants lack the enriched glutamic acid sequence found at the C-terminal domain ( Fig. 2a ). Visualization in HeLa cells showed that full length SVA-1 localizes predominantly in the cytoplasm, as opposed to the splice variants that are nuclear localized ( Fig. 2a ). Further, we tested these variants for antiviral activity and observed that they had decreased efficiency compared to full length SVA-1 (Fig. 2) . Full SVA-1 protein strongly co-localized with viral protein p24 in the cytoplasm ( Fig. 2e) with occasional cytoplasmic co-localization with Rev and Tat proteins (Extended Data Fig. 3 ).
The data suggest that the SVA-1 C-terminal portion contains a crucial domain that determines not only the localization of the protein but its antiviral activity as well.
Nuclear export is critical for the antiviral function of SVA-1. To assess the mechanism for the reduced antiviral activity of SVA-1 after C terminal truncation, we generated a panel of mutants ( Fig. 3 ).
When we assessed the ability of altered gene sequences to block the production of lentiviral vector particles, the data showed that both the full length protein and the altered NLS mutant were able to maintain antiviral function, whereas the mutants without C-terminal amino acids 74 and 104 significantly lost their ability to reduce viral production. Assessing how these alterations affected cellular localization of these proteins, C-terminal truncation also changed the localization to nuclear from cytoplasm, allowing us to identify a critical nuclear export signal (NES sequence 260-LLEDLDNLILE-270) within C-terminal that is required for antiviral activity. Together, these data suggest that the intact C-terminal domain is crucial for the antiviral activity of SVA-1.
SVA-1 antiviral function is conserved across species. Retroviruses have a broad host range and cells
have evolved conserved antiviral strategies to counteract infection. IFN-α is an effective inhibitor of diverse primate and non-primate lentiviruses, including SIV Mac , FIV, EIAV, and other retroviruses 22 . The SVA-1 protein is over 95% conserved amongst the mouse, chimpanzee, and human (Extended Data Fig.   4 ). Given this cross-species conservation, we investigated whether antiviral activity against lentiviral replication was also shared. C19ORF66 (SVA-1) maintained its antiviral property across these species in reducing intracellular viral particle production and release (Fig 4) . Taken together, SVA-1 forms a part of a well-conserved innate antiviral response. The SVA-1 protein homologues of murine and primate species can be expected to restrict lenti-or retro-viruses of respective species. Previous studies have shown that ISGs such as cGAS, MX2, and CNP possess broad spectrum anti-retroviral function 12, 14, 19 .
DISCUSSION

Inhibition of HIV-1 replication by interferon has been well recognized, however the downstream effector
ISGs mediating this activity remain to be fully understood. We utilized both authentic NL-43 wild type P a g e 1 1 o f 2 4
HIV-1 and VSV-G pseudotyped HIV-1 based lentivector system to provide a functional annotation of SVA-1. SVA-1 is an interferon-stimulated gene, as its expression was induced in human cells by IFN-α treatment. Previous studies have demonstrated that the IFN-α treatment of macrophages and T cells can block HIV-1 infection various steps ranging from reverse transcription to Env assembly to release of virions [22] [23] [24] [25] . IFN-α treatment predominantly interferes with the accumulation of reverse transcribed HIV-1 cDNA 26, 27 . This impairment can be reversed by proteasome inhibition suggesting a key role of the ubiquitin proteasome system 22 . Some defined mechanisms have included: APOBEC3G, a cytidine deaminase that causes mutations during viral reverse transcription 20 , SAMHD1, which reduces the intracellular pool of deoxynucleotide triphosphate (dNTPs) available for reverse transcription 18 , TRIM5α, which restricts viral capsid uncoating and enhances proteasome-mediated degradation 16 , and CNP, which interferes with virion assembly 14 . Here we add SVA-1 as an additional antiviral ISG.
We confirm SVA-1 to be an interferon-stimulated gene that suppresses HIV-1 replication via impairment of intracellular Gag protein synthesis resulting in a reduced viral particle release. We observe that the cytoplasmic localization of SVA-1 is critical for its antiviral function. Mutant SVA-1 protein and splice variants lacking a nuclear export signal in the C-terminal domain show loss of antiviral activity. Full length SVA-1 protein contains both NLS and NES sequences suggesting it can shuttle back and forth from cytoplasm to nucleus. This process could be regulated by nuclear export proteins CRM1 (Exportin 1) and RAN 28, 29 . HIV-1 protein Rev utilizes these nuclear export proteins for transferring unspliced and singly spliced HIV-1 transcripts to the cytoplasm from the nucleus. It is an interesting hypothesis to investigate the competitive inhibitory function of SVA-1 at this crucial stage of HIV-1 life cycle.
The precise mechanism of SVA-1 mediated inhibition of HIV-1 replication is requires further investigation. It will be interesting to study the SVA-1 effect on HIV regulatory proteins Tat and Rev in P a g e 1 2 o f 2 4
the context of viral genome transcription as well as export of un-spliced and singly-spliced viral RNA to the cytoplasm. Furthermore, SVA-1 protein may execute the function with direct or indirect interaction with viral and cellular proteins. Identification of interacting protein partners will shed light of the antiviral mechanism of the interferon stimulated SVA-1 factor. In summary, we have discovered the novel effector function of C19ORF66 as an inhibitor of HIV-1 replication. 
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